Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine

References

• Rappazzo CG, Watkins HC, Guarino CM, et al. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine. 2016;34:1252–1258.
   PubMed Web of Science ®Google Scholar
• Takashita E, Fujisaki S, Shirakura M, et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill. 2016;21. doi: 10.2807/1560-7917.ES.2016.21.24.30258.
   PubMedGoogle Scholar
• Imai M, Watanabe T, Kiso M, et al. A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe. 2017;22:615–626.
   PubMed Web of Science ®Google Scholar
• Schnitzler SU, Schnitzler P. An update on swine-origin influenza virus A/H1N1: a review. Virus Genes. 2009;39:279–292.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Influenza vaccine viruses and reagents. Available from: http://www.who.int/influenza/vaccines/virus/en/.
   Google Scholar
• Lamb RA, Choppin PW. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology. 1981;112:729–737.
   PubMed Web of Science ®Google Scholar
• Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell. 1992;69:517–528.
   PubMed Web of Science ®Google Scholar
• Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A. 2012;109:4269–4274.
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999;5:1157–1163.
   PubMed Web of Science ®Google Scholar
• Kim MC, Song JM, Eunju O, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther. 2013;21:485–492.
   PubMed Web of Science ®Google Scholar
• De Filette M, Martens W, Roose K, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem. 2008;283:11382–11387.
   PubMed Web of Science ®Google Scholar
• Eliasson DG, El Bakkouri K, Schön K, et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008;26:1243–1252.
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29:5145–5152.
   PubMed Web of Science ®Google Scholar
• Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol. 2007;37:2441–2449.
   PubMed Web of Science ®Google Scholar
• Kolpe A, Schepens B, Fiers W, et al. M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines. 2017;16:123–136.
   PubMed Web of Science ®Google Scholar
• Kou Y, Xu Y, Zhao Z, et al. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. Immunol Lett. 2017;190:51–57.
   PubMed Web of Science ®Google Scholar
• Alharbi NK, Padron-Regalado E, Thompson CP, et al. Chadox1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788.
   PubMed Web of Science ®Google Scholar
• Liang R, van den Hurk JV, Zheng C, et al. Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine. 2005;23:5252–5262.
   PubMed Web of Science ®Google Scholar
• Costa SM, Azevedo AS, Paes MV, et al. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology. 2007;358:413–423.
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988;62:2762–2772.
   PubMed Web of Science ®Google Scholar
• El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186:1022–1031.
   PubMed Web of Science ®Google Scholar
• Wang R, Song A, Levin J, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008;80:168–177.
   PubMed Web of Science ®Google Scholar
• Grandea AG, Olsen OA, Cox TC, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010;107:12658–12663.
   PubMed Web of Science ®Google Scholar
• Qiu M, Fang F, Chen Y, et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun. 2006;343:1124–1131.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu B, Chen Q, et al. Characterization of an H10N8 influenza virus isolated from Dongting lake wetland. Virol J. 2011;8:42.
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang H, Chen Q, et al. Characterization of low-pathogenic H6N6 avian influenza viruses in central China. Arch Virol. 2013;158:367–377.
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nature Biotechnology. 1998;16:867–870.
   PubMed Web of Science ®Google Scholar
• Sui Z, Chen Q, Wu R, et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol. 2010;155:535–544.
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008;26:201–214.
   PubMed Web of Science ®Google Scholar
• Sui Z, Chen Q, Fang F, et al. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine. 2010;28:7690–7698.
   PubMed Web of Science ®Google Scholar